Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical has revealed that interim results from a phase I/II study of 10 patients with recurrent breast cancer treated with its selective electrochemical tumor ablation (SECTA) therapy showed the therapy was safe, well-tolerated, and achieved a 75% complete tumor response rate.
Subscribe to our email newsletter
The open-label, single-treatment trial in patients with recurrent breast cancer following partial or complete mastectomy used intratumoral administration of bleomycin followed by electroporation, to enhance uptake of the drug using Inovio’s MedPulser system.
No treatment-related serious adverse events were observed.
“The result of this first organized study using SECTA to treat breast cancer has important clinical relevance and indicates the potential to use SECTA for an entirely new form of cancer,” stated Dr Paul Goldfarb, consulting medical director to Inovio.